Study highlights the significant enhancement in predicting common diseases like heart disease, diabetes, Alzheimer’s, and prostate cancer by integrating polygenic risk scores (PRSs) and gut microbiome scores with conventional risk factors, showcasing the potential of multiomic approaches in personalized medicine.
How Pfizer ended up passing on my GLP-1 work back in the early ’90s
One of the biopharma industry’s marvels of the 2020s has been the enormous medical and financial success of the GLP-1 class of drugs. But the